Download PDF

1. Company Snapshot

1.a. Company Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States.It offers ARCUS, a genome editing platform to cure genetic disorders.The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.


The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc.to develop ARCUS-based gene editing therapies.Precision BioSciences, Inc.


was incorporated in 2006 and is headquartered in Durham, North Carolina.

Show Full description

1.b. Last Insights on DTIL

The recent performance of Precision BioSciences, Inc. is negatively driven by the lack of a significant earnings beat in the most recent quarter. However, the company's gene editing platform has made progress with the reporting of clinical efficacy and safety data in the Phase 1/2 OTC-HOPE study, but this has not been enough to drive the stock's performance. Additionally, the company's treatment candidate PBGENE-HBV showed promising initial safety and antiviral activity, but this is a short-term positive that may not have a significant impact on the stock's performance. The company's focus on gene editing therapies is a positive long-term trend, but it may take time for this to translate into significant earnings growth.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Precision Biosciences: Still Swinging And Finally Drawing Blood

Dec -04

Source: seekingalpha.com

Card image cap

Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript

Nov -11

Source: seekingalpha.com

Card image cap

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Nov -10

Source: businesswire.com

Card image cap

Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep -16

Source: seekingalpha.com

Card image cap

DTIL Revenue Drops 99%

Aug -07

Source: fool.com

Card image cap

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

Aug -07

Source: zacks.com

Card image cap

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

May -15

Source: zacks.com

Card image cap

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

Apr -16

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.20%)

6. Segments

Loose and Packet Tea

Expected Growth: 11.3%

The 11.3% growth in Loose and Packet Tea from Precision BioSciences, Inc. is driven by increasing health-conscious consumers seeking natural and organic products, rising demand for specialty teas, and strategic partnerships expanding distribution channels. Additionally, innovative product offerings and targeted marketing campaigns have contributed to the segment's growth.

Macadamia Nuts

Expected Growth: 9.9%

Precision BioSciences' Macadamia Nuts growth is driven by increasing demand for healthy snacks, rising consumer awareness of nut-based products' nutritional benefits, and the company's innovative gene-editing technology enhancing crop yields and disease resistance. Additionally, expanding distribution channels and strategic partnerships contribute to the 9.9% growth.

Business Management and Consultancy

Expected Growth: 11.37%

Precision BioSciences, Inc.'s 11.37% growth in Business Management and Consultancy is driven by increasing demand for gene editing technologies, strategic partnerships, and expansion into new therapeutic areas. The company's proprietary ARCUS genome editing platform and expertise in gene therapy development are key differentiators, enabling it to capitalize on the growing gene editing market.

Other

Expected Growth: 10.58%

Precision BioSciences' 10.58% growth is driven by increasing adoption of its gene editing platform, ARCUS, in the gene therapy market. Strong partnerships with biotech and pharma companies, such as Novartis and Servier, are fueling revenue growth. Additionally, the company's expanding pipeline of gene-edited allogenic therapies and CAR-T cell therapies is contributing to its growth momentum.

7. Detailed Products

Arcus Genome Editing

A proprietary genome editing platform that utilizes a unique, highly precise, and efficient approach to make double-strand breaks in the genome, allowing for precise gene editing and gene regulation.

Alphalex T cells

A type of T cell therapy that utilizes a proprietary, off-the-shelf, allogenic T cell platform to target and eliminate cancer cells.

In vivo gene editing

A gene editing approach that utilizes the Arcus genome editing platform to make precise edits to genes in vivo, allowing for the treatment of genetic diseases.

Gene therapy

A therapeutic approach that utilizes the Arcus genome editing platform to deliver healthy copies of a gene to cells, allowing for the treatment of genetic diseases.

Cancer immunotherapy

A type of immunotherapy that utilizes the Alphalex T cell platform to target and eliminate cancer cells.

8. Precision BioSciences, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Precision BioSciences, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of gene editing technologies.

Bargaining Power Of Customers

The company's customers, primarily pharmaceutical and biotechnology companies, have limited bargaining power due to the specialized nature of Precision BioSciences' products and services.

Bargaining Power Of Suppliers

The company's suppliers, including providers of raw materials and equipment, have some bargaining power due to the specialized nature of their products, but Precision BioSciences' diversified supply chain mitigates this risk.

Threat Of New Entrants

The gene editing market is highly competitive, and new entrants with innovative technologies could potentially disrupt Precision BioSciences' market share.

Intensity Of Rivalry

The gene editing market is highly competitive, with several established players and new entrants vying for market share, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 62.38%
Debt Cost 4.35%
Equity Weight 37.62%
Equity Cost 12.00%
WACC 7.22%
Leverage 165.78%

11. Quality Control: Precision BioSciences, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Stoke Therapeutics

A-Score: 4.4/10

Value: 1.3

Growth: 5.2

Quality: 8.9

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
IGM Biosciences

A-Score: 3.8/10

Value: 9.4

Growth: 7.1

Quality: 4.3

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Shattuck Labs

A-Score: 3.6/10

Value: 7.8

Growth: 1.1

Quality: 3.8

Yield: 0.0

Momentum: 8.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Editas Medicine

A-Score: 3.3/10

Value: 6.2

Growth: 3.9

Quality: 3.6

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
AIM ImmunoTech

A-Score: 3.1/10

Value: 8.0

Growth: 4.3

Quality: 6.1

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Precision BioSciences

A-Score: 3.0/10

Value: 6.6

Growth: 5.0

Quality: 3.5

Yield: 0.0

Momentum: 1.5

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

5.02$

Current Price

5.02$

Potential

0.00%

Expected Cash-Flows